公开(公告)号：US09428567B2

公开(公告)日：2016-08-30

申请号：US13997503

申请日：2011-12-22

申请人： Kenan Christopher Garcia ,  Aron Levin ,  Aaron Ring

发明人： Kenan Christopher Garcia ,  Aron Levin ,  Aaron Ring

IPC分类号： C07K14/55 ,  A61K38/00

CPC分类号： C07K14/55 ,  A61K38/00

摘要： Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.

摘要翻译： 提供了新的人白介素-2（IL-2）突变蛋白或其变体，以及核酸分子及其变体。 还公开了产生这些突变蛋白的方法以及刺激动物的免疫系统的方法。 此外，本发明提供了包含本发明的核酸分子的重组表达载体和已经引入了表达载体的宿主细胞。 包括药物组合物，其包括治疗有效量的本发明的人IL-2突变蛋白和药学上可接受的载体。 IL-2突变蛋白可用于用于治疗癌症和刺激免疫应答的药物组合物中。

公开(公告)号：US20140046026A1

公开(公告)日：2014-02-13

申请号：US13997503

申请日：2011-12-22

申请人： Kenan Christopher Garcia ,  Aron Levin ,  Aaron Ring

发明人： Kenan Christopher Garcia ,  Aron Levin ,  Aaron Ring

IPC分类号： C07K14/55

CPC分类号： C07K14/55 ,  A61K38/00

摘要： Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.

摘要翻译： 提供了新的人白介素-2（IL-2）突变蛋白或其变体，以及核酸分子及其变体。 还公开了产生这些突变蛋白的方法以及刺激动物的免疫系统的方法。 此外，本发明提供了包含本发明的核酸分子的重组表达载体和已经引入了表达载体的宿主细胞。 包括药物组合物，其包括治疗有效量的本发明的人IL-2突变蛋白和药学上可接受的载体。 IL-2突变蛋白可用于用于治疗癌症和刺激免疫应答的药物组合物中。

公开(公告)号：US20140105855A1

公开(公告)日：2014-04-17

申请号：US14009904

申请日：2012-04-06

申请人： Kenan Christopher Garcia

发明人： Kenan Christopher Garcia

IPC分类号： C07K14/54

CPC分类号： C07K14/54 ,  A61K38/00 ,  C07H21/00 ,  C07K2319/00 ,  C07K2319/21

摘要： IL-17 Receptor binding proteins, including non-naturally occurring and recombinantly modified proteins, methods of making and using such molecules as therapeutic, prophylactic and diagnostic agents are provided.

摘要翻译： 提供IL-17受体结合蛋白，包括非天然存在和重组修饰的蛋白质，制备和使用这些分子的治疗剂，预防剂和诊断剂的方法。